Go Pro
→ Major Buy Alert Issued for August 31st (From TradeSmith) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
$0.08
+62.7%		$0.02
$0.01
▼
$0.08
$5.83M9.37255,031 shs396,664 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
0.00%+158.57%+730.00%+730.00%+603.39%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
$0.08
+62.7%		$0.02
$0.01
▼
$0.08
$5.83M9.37255,031 shs396,664 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
0.00%+158.57%+730.00%+730.00%+603.39%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
$12.45M0.47N/AN/A($0.94) per share-0.09
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
-$7.49M-$0.09N/AN/AN/A-38.78%N/A-31.18%N/A

Latest EMMA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
N/A$0.02N/A$0.02N/A$6.32 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
N/A
0.09
0.07

Institutional Ownership

CompanyInstitutional Ownership
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
7.42%

Insider Ownership

CompanyInsider Ownership
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
35.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
6070.19 million45.62 millionNot Optionable

Recent News About These Companies

Emmaus Life Sciences Reports Quarterly Financial Results
May 15, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260515831708/en/emmaus-life-sciences-reports-quarterly-financial-results/
Emmaus Life Sciences Reports Annual Financial Results
March 30, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260330024056/en/emmaus-life-sciences-reports-annual-financial-results/
Emmaus Enters License and Exclusive Distribution Agreement with NeoImmuneTech
January 2, 2026  |  contractpharma.comC
Emmaus Life Sciences grants NeoImmuneTech Endari distribution rights
December 31, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/emmaus-life-sciences-grants-neoimmunetech-endari-distribution-rights/ar-AA1Tm4Ay
Emmaus Life Sciences enters license, distribution agreement with NeoImmuneTech
December 31, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/emmaus-life-sciences-enters-license-distribution-agreement-with-neoimmunetech/ar-AA1TjmxL
Emmaus, NIT sign Endari distribution agreement
December 31, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/emmaus-nit-sign-endari-distribution-095716124.html?fr=sycsrp_catchall
Emmaus Life Sciences restructures convertible debt via exchange
December 22, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/emmaus-life-sciences-restructures-convertible-debt-via-exchange?utm_source=marketbeat.com&utm_medium=referral
Emmaus Life Sciences Reports Quarterly Financial Results
November 14, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/emmaus-life-sciences-reports-quarterly-financial-results-302616058.html
Emmaus Life Sciences Reports Quarterly Financial Results
August 14, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/emmaus-life-sciences-reports-quarterly-financial-results-302530517.html
Emmaus Life Sciences Inc. Annual Income Statement - MarketWatch
July 9, 2025  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/emma/financials
Emmaus Life Sciences, Inc.: Emmaus Life Sciences Receives FDA Approval for Endari Label Enhancements - FinanzNachrichten.de
June 28, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-06/65764356-emmaus-life-sciences-inc-emmaus-life-sciences-receives-fda-approval-for-endari-label-enhancements-008.htm
Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements
June 26, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/emmaus-life-sciences-receives-fda-approval-for-endari-label-enhancements-302491840.html
Emmaus Life Sciences Reports Quarterly Financial Results
May 15, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/emmaus-life-sciences-reports-quarterly-financial-results-302457162.html
Emmaus Life Sciences Inc
April 18, 2025  |  uk.investing.comhttps://uk.investing.com/pro/OTCPK:EMMA/explorer/ebitda
Emmaus Life Science Reports Grant of Endari Market Exclusivity In Kingdom of Saudi Arabia
January 29, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/emmaus-life-science-reports-grant-143000492.html
Emmaus Life Sciences, Inc.: Emmaus Life Sciences Reports Improved Quarterly Financial Results
November 23, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-11/63866824-emmaus-life-sciences-inc-emmaus-life-sciences-reports-improved-quarterly-financial-results-008.htm
Emmaus Life Sciences Reports Improved Quarterly Financial Results
November 19, 2024  |  prnewswire.comhttps://www.prnewswire.com/news-releases/emmaus-life-sciences-reports-improved-quarterly-financial-results-302310615.html
Mike Johnson impersonates Trump: ‘Make it too big to rig’
November 7, 2024  |  uk.news.yahoo.comhttps://uk.news.yahoo.com/mike-johnson-impersonates-trump-too-211448466.html
Jesse Green secures another term in Senate District 24 in Boone, Greene and Guthrie counties
November 6, 2024  |  freep.comF
Emmaus, PA 10-Day Weather Forecast
November 2, 2024  |  wunderground.comW

Media Sentiment Over Time

Emmaus Life Sciences stock logo

Emmaus Life Sciences OTCMKTS:EMMA

$0.08 +0.03 (+62.75%)
As of 08/28/2026 03:55 PM Eastern

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas